Downregulating SR-B1 by using G1 to target GPER or by using metformin appears to be worth investigating since the former might affect endothelial cells more than hepatic cells and the latter has a beneficial therapeutic profile in type 2 diabetes. The gene discussed is SCARB1; the disease is type 2 diabetes mellitus.